US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

38

SUMMIT, N.J.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24CELG&src=ctag" target="_blank">$CELG</a> <a href="https://twitter.com/hashtag/MS?src=hash" target="_blank">#MS</a>–Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multiple sclerosis (RMS) in the United States. The European Medicines Agency (EMA) also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) in the European http://www.businesswire.com/news/home/20190606005133/en/FDA-EMA-Accept-Applications-Ozanimod-Treatment-Relapsing/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==